ArticleMedicine2026
Clinical risk factors associated with poor prognosis in gastric cancer patients with peritoneal metastasis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A risk prediction model for metachronous peritoneal metastasis after radical gastrectomy in gastric cancer based on peripheral blood inflammatory markers and tumor pathological features.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study aimed to identify clinical risk factors associated with poor prognosis in elderly patients with gastric cancer with peritoneal metastasis. A total of 150 patients aged ≥65 years, treated at our institution between January 2019 and December 2023, were included. Eligible patients had histopathologically confirmed gastric adenocarcinoma with peritoneal metastasis verified by intraoperative findings, cytology, or imaging. Clinical, pathological, and laboratory data - including peritoneal implantation stage, ascites grade, Eastern Cooperative Oncology Group performance status, serum albumin, hemoglobin, neutrophil-to-lymphocyte ratio, and treatment modalities - were collected and analyzed. Survival outcomes were evaluated using Kaplan-Meier and Cox proportional-hazards regression analyses. The median overall survival was 8.3 months. Univariate and multivariate analyses identified advanced peritoneal implantation stage (P2-P3), higher ascites grade (moderate-massive), Eastern Cooperative Oncology Group ≥2, hypoalbuminemia (<35 g/L), and elevated neutrophil-to-lymphocyte ratio (≥3) as independent predictors of poor overall survival (P < .05). By contrast, systemic chemotherapy and palliative surgery were independently associated with improved survival. These findings indicate that both tumor burden-related and host condition-related parameters significantly affect prognosis. Comprehensive assessment incorporating peritoneal stage, ascites grade, functional status, and inflammatory markers may facilitate individualized therapeutic strategies and prognostic stratification in elderly patients with gastric cancer with peritoneal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.